Advancing Health Through Science
At telolab, we blend technology and research to enhance your wellbeing.
Trusted Research
Rigorous studies ensuring every supplement supports your well-being.
Antioxidant ActivityNRF2 / ROS PATHWAYTELOLAB™ activates the Nrf2 transcription factor — the master cellular antioxidant switch — inducing SOD, CAT, HO-1, and NQO1 enzymes. Active contributors include Astragalus membranaceus, Vitis sp., astaxanthin from Haematococcus pluvialis, and additional proprietary co-actives within the matrix.10.55%ROS reduction in RAW 264.7 macrophage cells at 500 µg/mL (DCFH-DA, p<0.01)Dose-dep.S. cerevisiae survival under H₂O₂ oxidative stress (in vivo model)
10.55%
ROS reduction in RAW 264.7 macrophage cells at 500 µg/mL (DCFH-DA, p<0.01)
Dose-dep.
S. cerevisiae survival under H₂O₂ oxidative stress (in vivo model)
Anti-Inflammatory
NF-ΚB / CYTOKINE REGULATION
Bidirectional cytokine modulation: simultaneously suppresses pro-inflammatory IL-6 and TNF-α while upregulating anti-inflammatory IL-10 — achieving immune homeostasis rather than immune suppression. Uniquely important as IL-6 drives telomere shortening via STAT3 pathway.
73.65%
IL-6 suppression (ELISA, LPS-stimulated RAW 264.7, p<0.001)
40.17%
TNF-α reduction at equivalent conditions
+32.42%
IL-10 upregulation — anti-inflammatory immune balance
Telomere Extension
TERT / TELOMERASE ACTIVATION
Demonstrated telomere length extension in HeLa cells via two synergistic pathways: (1) Direct telomerase activation — cycloastragenol and astragaloside IV from A. membranaceus increase TERT mRNA expression; (2) Indirect protection — reduced ROS and IL-6 slow oxidative telomeric DNA damage. Measured by qRT-PCR ΔΔCq method (gold standard).
+58.5%
Telomere length increase in HeLa cells at 125 µg/mL (qRT-PCR, p<0.001)
Dual
Direct (TERT) + Indirect (oxidative protection) mechanism
Selective Anti-Cancer
PI3K/AKT/MTOR · STAT3 · APOPTOSIS
TELOLAB™ demonstrates selective cytotoxicity against 5 human cancer cell lines while maintaining >80% normal cell viability at equivalent concentrations. Mechanisms include PI3K/AKT/mTOR, MAPK/ERK, STAT3 inhibition and apoptosis induction. Multi-pathway inhibition reduces potential for drug resistance.
87.78
IC₅₀ µg/mL against MCF-7 breast cancer (MTT Assay, 72h)
>80%
Normal RAW 264.7 cell viability at equivalent concentrations
Stay Updated
Join telolab’s newsletter for the latest research and health supplement insights.